Recent Updates
Recently added Catalysts
RLAY Neutral Sentiment Score: 50/100

Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights

Thursday, April 27, 2023 1 min read
Key Takeaway: CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2

Market Sentiment Analysis

Full Press Release Details

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2023 financial results and corporate highlights after the close of market on Thursday, May 4, 2023. The company will not be conducting a teleconference in conjunction with its financial results press release.
About Relay Therapeutics

Frequently Asked Questions

What is Relay Therapeutics?

Relay Therapeutics is a biopharma company focusing on innovative drug development.

Who is the contact for Relay Therapeutics?

Caroline Glen is the contact person at Relay Therapeutics.

How can I reach Relay Therapeutics media contact?

You can contact Dan Budwick for media inquiries.

What is Caroline Glen's phone number?

Caroline Glen can be reached at 617-370-8837.

What is Dan Budwick's email address?

Dan Budwick's email address is dan@1abmedia.com.

Tags: RLAY Viatris Investor Conferences Healthcare Relay Therapeutics financial results corporate highlights 2023
Last updated: Apr 27, 2023